Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2023 · 10-Q
Revenue$141.00K$141.00K+51.6% vs Q3 2022 Net Income-$9.73M-$9.73MN/M vs Q3 2022 EPS Diluted-$0.22-$0.22N/M vs Q3 2022 Operating Income-$10,820,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$8,272,000N/M Margins · derivedOperating margin-7673.8%+1996.1 pt vs Q3 2022
Net margin-6901.4%+2314.7 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 2, 2023 · 33 d after period end